stockrowBioStem Technologies, Inc.
BSEM Healthcare Biotechnology
- Revenue
- −28.0%
- EPS
- −86,766.7%
Quarter to June 2026, against a year earlier
Follow BSEM
Alert me
BioStem Technologies, Inc. (BSEM) EV/Sales
As of 6 November 2026, BioStem Technologies, Inc. (BSEM) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from 0.0× (June 2024) to 2.2× (September 2026); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.3× | (56.12%) |
| FY2024 | 0.8× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 42.51% |
| Mar 2026 | 1.0× | 209.41% |
| Dec 2025 | 0.3× | (17.49%) |
| Sep 2025 | 0.4× | (50.01%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −174× |
| KTTA Pasithea Therapeutics Corp. compare | −55.8× |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| BSEM BioStem Technologies, Inc. | 0.4× |
| COCP Cocrystal Pharma, Inc. compare | 9.0× |
| MCRB Seres Therapeutics, Inc. compare | 49.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)